Aspirin Didn T Improve Survival For Hospitalized Covid 19 Patients Study Finds
Researchers studied 1,557 critically ill COVID-19 patients from an ongoing trial. Thirty-four percent were women and the average age was 57. Patients were randomly assigned to take either aspirin, a P2Y12 inhibitor, or no antiplatelet therapy for up to 14 days. The study concluded among the critically ill patients with COVID-19, those that received blood-thinning treatment compared with no antiplatelet agent, “had a low likelihood of providing improvement in the number of organ support-free days within 21 days....